SANGUINE BIOSCIENCES, INC

Sanguine Biosciences, Inc. specializes in the development and execution of biospecimen collection protocols for clinical research, with demonstrated expertise in conjunctival swab matrix sampling and prospective biological sample acquisition. Their technical capabilities center on sterile, standardized collection methodologies for diagnostic and surveillance applications, ensuring sample integrity for downstream molecular analysis. The company applies rigorous biosafety and chain-of-custody protocols to support sensitive public health studies, with a focus on non-invasive sampling techniques that enhance participant compliance and data reliability. Their work reflects deep familiarity with clinical trial logistics, biospecimen handling standards, and regulatory-aligned documentation practices essential for FDA- and CDC-aligned research initiatives. Sanguine Biosciences has delivered services directly to the Department of Health and Human Services, primarily supporting public health surveillance and infectious disease research programs. Their engagement reflects a focused partnership in collecting clinically relevant biological matrices under controlled, prospective study designs, indicating alignment with HHS agencies such as CDC or NIH in advancing diagnostic innovation and epidemiological data collection. The contractor’s primary industry focus is in medical laboratories (NAICS 621511), where they operate at the intersection of clinical sampling and laboratory diagnostics. Their niche lies in the pre-analytical phase of testing—ensuring high-quality specimen acquisition that enables accurate molecular detection, particularly for respiratory and ocular pathogens. This positions them as a specialized provider in biospecimen logistics rather than analytical testing, serving as a critical link in the diagnostic research pipeline. Sanguine Biosciences is a small, privately held entity headquartered in Woburn, Massachusetts. While currently holding no formal government certifications, their operational model is built on strict adherence to clinical laboratory standards and biospecimen handling best practices. Their geographic base in the Boston biotech corridor supports proximity to academic medical centers and federal research partners, reinforcing their role as a niche supplier in the federal health research ecosystem.